文献速递泌尿男性生殖肿瘤支持与姑息治疗

新诊断高危局限或转移性激素敏感性前列腺癌中骨折相关住院:基于医疗系统数据的STAMPEDE多西他赛与唑来膦酸III期试验二次分析

Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data.
PubMed 文献 · Ann Oncol · 2025-07-16

基于STAMPEDE试验中英格兰招募患者(2042例,M0 734例、M1 1308例)的医疗系统数据,评估ADT基础上加用唑来膦酸和多西他赛对骨折相关住院的影响。M1患者中唑来膦酸显著降低骨折风险(SDHR 0.73,95%CI 0.55-0.97,P=0.015),M0患者无显著效果;多西他赛对M0和M1均无明确影响。

要点

  • 仅ADT治疗M0患者5年骨折累积发生率11%,M1患者23%;M0患者10年为26%。
  • M1患者加用唑来膦酸显著降低骨折风险(SDHR 0.73,95%CI 0.55-0.97,P=0.015)。
  • M0患者加用唑来膦酸未见显著效果,多西他赛对M0和M1均无明确影响。

核心结论

  • 接受ADT的M0和M1前列腺癌患者骨折累积发生率均较高,M1患者加用唑来膦酸可显著降低长期骨折风险,M0患者无明确效果。
  • 这些数据支持在M1前列腺癌接受ADT的男性中使用骨保护剂以降低骨折风险。

研究设计与样本

  • STAMPEDE III期试验的二次分析,获取英格兰招募患者的医疗系统数据。
  • 比较标准治疗ADT与ADT加唑来膦酸或多西他赛或两者联合。
  • 采用ICD10诊断和OPCS手术编码从住院记录中识别骨折相关住院。
  • 使用灵活参数竞争风险模型估计5年和10年累积发生率及亚分布风险比(SDHR)。
  • 2705例英格兰招募患者中2140例(79%)符合二次分析条件,2042/2140例(96%)有链接数据(M0 734例,M1 1308例)。

主要发现

  • 仅ADT治疗的M0患者5年骨折累积发生率为11%(95%CI 8%-15%),M1患者为23%(95%CI 19%-28%)。
  • M0患者10年骨折累积发生率为26%(95%CI 20%-33%)。
  • M1患者加用唑来膦酸显著降低骨折风险(SDHR 0.73,95%CI 0.55-0.97,P=0.015)。
  • M0患者加用唑来膦酸未显著降低骨折风险(SDHR 0.88,95%CI 0.59-1.32,P=0.549)。
  • 多西他赛对M0(P=0.570)和M1(P=0.264)患者骨折风险均无明确影响。

临床怎么用

  • 作者认为这些数据支持在M1前列腺癌接受ADT的男性中使用骨保护剂以降低骨折风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT), the mainstay systemic treatment for high risk non-metastatic (M0) and metastatic (M1) prostate cancer is associated with bone loss and increased fracture risk. The STAMPEDE trial tested the addition of zoledronic acid (ZA) ± docetaxel (with prednisolone) to ADT. Both regimens may impact bone health. However, long-term fracture incidence remains uncertain. PATIENTS AND METHODS: Health systems data were obtained for patients recruited from England and randomised to standard-of-care (SOC) ADT compared with SOC plus ZA or docetaxel or both docetaxel and ZA. ICD10 diagnosis and OPCS procedure codes from inpatient hospital admissions were used to identify fracture-related hospitalisations. Flexible parametric competing risks models were used to estimate 5- and 10-year cumulative incidence and sub-distribution hazard ratios (SDHR). RESULTS: 2140 of 2705 (79%) patients recruited from trial sites in England were eligible for this secondary analysis. Linked data were available for 2042/2140 (96%) pts (734 M0, 1308 M1). 5-year cumulative incidence of fracture for M0 and M1 patients treated with SOC only was 11% [95% confidence interval (CI), 8% to 15%] and 23% (95% CI, 19% to 28%), respectively. 10-year cumulative incidence in M0 patients was 26% (95% CI, 20% to 33%). Allocation to ZA significantly reduced the risk of fracture in M1 patients (SDHR 0.73, 95% CI 0.55-0.97; P = 0.015) but not M0 patients (SDHR 0.88, 95% CI 0.59-1.32; P = 0.549). Docetaxel had no clear effect on the risk of fracture in M0 (P = 0.570) or M1 (P = 0.264) patients. CONCLUSIONS: High cumulative incidence of fracture was observed in both M0 and M1 prostate cancer patients receiving ADT. The addition of ZA to ADT ± docetaxel significantly reduced long-term fracture risk in M1 participants but had no clear effect in M0 disease. These data support the use of bone protective agents to reduce fracture risk in men with M1 prostate cancer undergoing ADT.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Jones C, Dutey-Magni P, Murphy LR, et al. Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data. Ann Oncol. 2025. PMID: 40680994. doi:10.1016/j.annonc.2025.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。